138 related articles for article (PubMed ID: 38219810)
1. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation.
Hopkins AM; Modi ND; Rockhold FW; Hoffmann T; Menz BD; Veroniki AA; McKinnon RA; Rowland A; Swain SM; Ross JS; Sorich MJ
J Clin Epidemiol; 2024 Mar; 167():111263. PubMed ID: 38219810
[TBL] [Abstract][Full Text] [Related]
2. Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration.
Modi ND; Abuhelwa AY; McKinnon RA; Boddy AV; Haseloff M; Wiese MD; Hoffmann TC; Perakslis ED; Rowland A; Sorich MJ; Hopkins AM
JAMA Oncol; 2022 Sep; 8(9):1310-1316. PubMed ID: 35900732
[TBL] [Abstract][Full Text] [Related]
3. Access to regulatory data from the European Medicines Agency: the times they are a-changing.
Wieseler B; McGauran N; Kerekes MF; Kaiser T
Syst Rev; 2012 Oct; 1():50. PubMed ID: 23110993
[TBL] [Abstract][Full Text] [Related]
4. Clinical study reports published by the European Medicines Agency 2016-2018: a cross-sectional analysis.
Byrne D; Prendergast C; Fahey T; Moriarty F
BMJ Open; 2023 May; 13(5):e068981. PubMed ID: 37188475
[TBL] [Abstract][Full Text] [Related]
5. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
Miller J; Ross JS; Wilenzick M; Mello MM
BMJ; 2019 Jul; 366():l4217. PubMed ID: 31292127
[TBL] [Abstract][Full Text] [Related]
6. European Medicines Agency Policy 0070: an exploratory review of data utility in clinical study reports for academic research.
Ferran JM; Nevitt SJ
BMC Med Res Methodol; 2019 Nov; 19(1):204. PubMed ID: 31690260
[TBL] [Abstract][Full Text] [Related]
7. Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability.
Hopkins AM; Rowland A; Sorich MJ
BMC Med; 2018 Sep; 16(1):165. PubMed ID: 30261889
[TBL] [Abstract][Full Text] [Related]
8. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
9. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
10. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports.
Schroll JB; Abdel-Sattar M; Bero L
J Clin Epidemiol; 2015 Jan; 68(1):102-7. PubMed ID: 25150193
[TBL] [Abstract][Full Text] [Related]
11. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.
Boesen K; Gøtzsche PC; Ioannidis JPA
Epidemiol Psychiatr Sci; 2021 Apr; 30():e35. PubMed ID: 33926608
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
Deane BR; Porkess S
Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
[TBL] [Abstract][Full Text] [Related]
13. Data-sharing and re-analysis for main studies assessed by the European Medicines Agency-a cross-sectional study on European Public Assessment Reports.
Siebert M; Gaba J; Renault A; Laviolle B; Locher C; Moher D; Naudet F
BMC Med; 2022 May; 20(1):177. PubMed ID: 35590360
[TBL] [Abstract][Full Text] [Related]
14. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
15. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data.
Wieseler B; Wolfram N; McGauran N; Kerekes MF; Vervölgyi V; Kohlepp P; Kamphuis M; Grouven U
PLoS Med; 2013 Oct; 10(10):e1001526. PubMed ID: 24115912
[TBL] [Abstract][Full Text] [Related]
16. The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions.
De Wilde B; Barry E; Fox E; Karres D; Kieran M; Manlay J; Ludwinski D; Reaman G; Kearns P
J Clin Oncol; 2022 Oct; 40(29):3456. PubMed ID: 35947814
[TBL] [Abstract][Full Text] [Related]
17. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis.
Axson S; Mello MM; Lincow D; Yang C; Gross C; Ross JS; Miller J
BMJ Open; 2021 Jul; 11(7):e053248. PubMed ID: 34281933
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement.
Danchev V; Min Y; Borghi J; Baiocchi M; Ioannidis JPA
JAMA Netw Open; 2021 Jan; 4(1):e2033972. PubMed ID: 33507256
[TBL] [Abstract][Full Text] [Related]
20. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
Naci H; Davis C; Savović J; Higgins JPT; Sterne JAC; Gyawali B; Romo-Sandoval X; Handley N; Booth CM
BMJ; 2019 Sep; 366():l5221. PubMed ID: 31533922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
